Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
211.38
-0.20 (-0.09%)
At close: Aug 25, 2026, 4:00 PM EDT
210.88
-0.50 (-0.24%)
Pre-market: Aug 26, 2026, 7:00 AM EDT

Revolution Medicines Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---11.5835.3829.39
Revenue Growth
----67.27%20.38%-31.62%
Gross Profit
-1,296-987.33-592.23-407.86-217.69-157.56
Operating Income
-1,627-1,182-689.52-475.99-258.28-188.01
Net Income
-1,768-1,131-600.09-436.37-248.71-187.09
Earnings Per Share
-8.92-5.95-3.58-3.86-3.08-2.57
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3,9382,0262,2891,853644.94577.05
Total Debt
1,190427.15135.8487.9464.2166.63
Net Cash (Debt)
2,7471,5992,1531,765580.74510.42
Net Cash Growth
56.17%-25.77%22.01%203.93%13.78%25.08%
Net Cash Per Share
13.868.4112.8415.607.207.01

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-1,223-897.74-557.44-350.57-224.4-147.18
Capital Expenditures
-9.1-15.99-10.31-7.73-10.82-6.53
Free Cash Flow
-1,232-913.73-567.74-358.3-235.22-153.71
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
----4110.41%-730.01%-639.70%
Pretax Margin
----3798.71%-704.14%-636.58%
Profit Margin
----3768.28%-702.95%-636.58%
FCF Margin
----3094.14%-664.83%-522.99%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---407.5859.7863.11